Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia. (4th February 2022)

• Record Type: Journal Article
• Authors: Lyski, Zoe L.; Kim, Myung Sun; Xthona Lee, David; Sampson, David; Raué, Hans-Peter; Raghunathan, Vikram; Ryan, Debbie; Brunton, Amanda E.; Slifka, Mark K.; Messer, William B.; Spurgeon, Stephen E.
• Other Names: Piccaluga Pier Paolo Academic Editor.
• Is Part Of: Case reports in hematology. Volume 2022(2022)
• Publication Date: 2022-02-04
• Subjects: Hematology -- Periodicals; Hematology -- Case studies -- Periodicals; Blood -- Diseases -- Periodicals; Hematology; Hematologic Diseases; Blood -- Diseases; Hematology; Electronic journals; Periodicals; Case studies; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 616.15
• DOI: 10.1155/2022/6831640
• Languages: English
• ISSNs: 2090-6560

Abstract

Abstract : Individuals with chronic lymphocytic leukemia (CLL) have significant immune disfunction, often further disrupted by treatment. While currently available COVID-19 vaccinations are highly effective in immunocompetent individuals, they are often poorly immunogenic in CLL patients. It is important to understand the role a heterologous boost would have in patients who did not respond to the initial two-dose mRNA vaccine series. SARS-CoV-2 specific immune responses, including antibodies and memory B-cells, CD4 and CD8 T-cells were assessed prior to vaccination, as well as postinitial vaccination series and post-third dose in two subjects. One subject seroconverted, had RBD-specific memory B-cells and spike-specific CD4 T-cells while the other did not. Both subjects had a spike-specific CD8 T-cell response after the original mRNA vaccination series that was further boosted after the third dose or remained stable. The results of this study, however small, are especially promising to CLL individuals who did not seroconvert following the initial mRNA vaccination series.